Complement inhibition does not impair the clinical antiviral capabilities of virus-specific T-cell therapy

Blood Adv. 2020 Jul 28;4(14):3252-3257. doi: 10.1182/bloodadvances.2020002252.

Jeremy D Rubinstein^{1

2}, Xiang Zhu³, Carolyn Lutzko^{1

3}, Tom Leemhuis⁴, Jose A Cancelas^{1

3

4}, Sonata Jodele^{1

2}, Catherine M Bollard^{5

6}, Patrick J Hanley^{5

6}, Stella M Davies^{1

2}, Michael S Grimley^{1

2}, Adam S Nelson^{1

2}

¹ Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, OH.
² Division of Bone Marrow Transplantation and Immune Deficiency and.
³ Division of Experimental Hematology, Cancer and Blood Disease Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
⁴ Hoxworth Blood Center, University of Cincinnati, Cincinnati, OH.
⁵ Center for Cancer and Immunology Research, Children's National Health System, Washington, DC; and.
⁶ Department of Pediatrics, The George Washington University, Washington, DC.

Abstract

The use of terminal complement blockade is compatible with virus-specific T-cell (VST) expansion and clinical effectiveness.
VST and complement-blocking agent concurrent therapy may be safely used in patients with thrombotic microangiopathy and viral infections.